Anticancer innovative therapy congress: Highlights from the 10th anniversary edition

Francesca De Santis; Giovanni Fucà; Dirk Schadendorf; Alberto Mantovani; Luca Magnani; Michael Lisanti; Stephen Pettitt; Matteo Bellone; Giannino Del Sal; Saverio Minucci; Alexander Eggermont; Paolo Bruzzi; Silvio Bicciato; Pierfranco Conte; Roberta Noberini; John Hiscott; Filippo De Braud; Michele Del Vecchio; Massimo Di Nicola

doi:10.1016/j.cytogfr.2021.02.001

Anticancer innovative therapy congress: Highlights from the 10th anniversary edition

Francesca De Santis, Giovanni Fucà, Dirk Schadendorf, Alberto Mantovani, Luca Magnani, Michael Lisanti, Stephen Pettitt, Matteo Bellone, Giannino Del Sal, Saverio Minucci, Alexander Eggermont, Paolo Bruzzi, Silvio Bicciato, Pierfranco Conte, Roberta Noberini, John Hiscott, Filippo De Braud, Michele Del Vecchio, Massimo Di Nicola

Research related

Research output: Contribution to journal › Review article › peer-review

4 Citations (Scopus)

Abstract

During the Tenth Edition of the Annual Congress on “Anticancer Innovative Therapy” [Milan, 23/24 January 2020], experts in the fields of immuno-oncology, epigenetics, tumor cell signaling, and cancer metabolism shared their latest knowledge on the roles of i] epigenetics, and in particular, chromatin modifiers, ii] cancer metabolism, iii] cancer stem cells [CSCs], iv] tumor cell signaling, and iv] the immune system. The novel therapeutic approaches presented included epigenetic drugs, cell cycle inhibitors combined with ICB, antibiotics and other off-label drugs, small-molecules active against CSCs, liposome-delivered miRNAs, tumor-specific CAR-T cells, and T-cell–based immunotherapy. Moreover, important evidence on possible mechanisms of resistance to these innovative therapies were also discussed, in particular with respect to resistance to ICB. Overall, this conference provided scientists and clinicians with a broad overview of future challenges and hopes to improve cancer treatment reasonably in the medium-short term.

Original language	English
Pages (from-to)	1-8
Number of pages	8
Journal	Cytokine and Growth Factor Reviews
Volume	59
DOIs	https://doi.org/10.1016/j.cytogfr.2021.02.001
Publication status	Published - Jun 2021

Keywords

Innovative therapy
Targeted therapy

Access to Document

10.1016/j.cytogfr.2021.02.001

Cite this

De Santis, F., Fucà, G., Schadendorf, D., Mantovani, A., Magnani, L., Lisanti, M., Pettitt, S., Bellone, M., Del Sal, G., Minucci, S., Eggermont, A., Bruzzi, P., Bicciato, S., Conte, P., Noberini, R., Hiscott, J., De Braud, F., Del Vecchio, M., & Di Nicola, M. (2021). Anticancer innovative therapy congress: Highlights from the 10th anniversary edition. Cytokine and Growth Factor Reviews, 59, 1-8. https://doi.org/10.1016/j.cytogfr.2021.02.001

@article{f29e296c6eed4effabd2183f03f1b83d,

title = "Anticancer innovative therapy congress: Highlights from the 10th anniversary edition",

abstract = "During the Tenth Edition of the Annual Congress on “Anticancer Innovative Therapy” [Milan, 23/24 January 2020], experts in the fields of immuno-oncology, epigenetics, tumor cell signaling, and cancer metabolism shared their latest knowledge on the roles of i] epigenetics, and in particular, chromatin modifiers, ii] cancer metabolism, iii] cancer stem cells [CSCs], iv] tumor cell signaling, and iv] the immune system. The novel therapeutic approaches presented included epigenetic drugs, cell cycle inhibitors combined with ICB, antibiotics and other off-label drugs, small-molecules active against CSCs, liposome-delivered miRNAs, tumor-specific CAR-T cells, and T-cell–based immunotherapy. Moreover, important evidence on possible mechanisms of resistance to these innovative therapies were also discussed, in particular with respect to resistance to ICB. Overall, this conference provided scientists and clinicians with a broad overview of future challenges and hopes to improve cancer treatment reasonably in the medium-short term.",

keywords = "Innovative therapy, Targeted therapy",

author = "{De Santis}, Francesca and Giovanni Fuc{\`a} and Dirk Schadendorf and Alberto Mantovani and Luca Magnani and Michael Lisanti and Stephen Pettitt and Matteo Bellone and {Del Sal}, Giannino and Saverio Minucci and Alexander Eggermont and Paolo Bruzzi and Silvio Bicciato and Pierfranco Conte and Roberta Noberini and John Hiscott and {De Braud}, Filippo and {Del Vecchio}, Michele and {Di Nicola}, Massimo",

note = "Publisher Copyright: {\textcopyright} 2021",

year = "2021",

month = jun,

doi = "10.1016/j.cytogfr.2021.02.001",

language = "English",

volume = "59",

pages = "1--8",

journal = "Cytokine and Growth Factor Reviews",

issn = "1359-6101",

publisher = "Elsevier Ltd.",

}

De Santis, F, Fucà, G, Schadendorf, D, Mantovani, A, Magnani, L, Lisanti, M, Pettitt, S, Bellone, M, Del Sal, G, Minucci, S, Eggermont, A, Bruzzi, P, Bicciato, S, Conte, P, Noberini, R, Hiscott, J, De Braud, F, Del Vecchio, M & Di Nicola, M 2021, 'Anticancer innovative therapy congress: Highlights from the 10th anniversary edition', Cytokine and Growth Factor Reviews, vol. 59, pp. 1-8. https://doi.org/10.1016/j.cytogfr.2021.02.001

TY - JOUR

T1 - Anticancer innovative therapy congress

T2 - Highlights from the 10th anniversary edition

AU - De Santis, Francesca

AU - Fucà, Giovanni

AU - Schadendorf, Dirk

AU - Mantovani, Alberto

AU - Magnani, Luca

AU - Lisanti, Michael

AU - Pettitt, Stephen

AU - Bellone, Matteo

AU - Del Sal, Giannino

AU - Minucci, Saverio

AU - Eggermont, Alexander

AU - Bruzzi, Paolo

AU - Bicciato, Silvio

AU - Conte, Pierfranco

AU - Noberini, Roberta

AU - Hiscott, John

AU - De Braud, Filippo

AU - Del Vecchio, Michele

AU - Di Nicola, Massimo

PY - 2021/6

Y1 - 2021/6

N2 - During the Tenth Edition of the Annual Congress on “Anticancer Innovative Therapy” [Milan, 23/24 January 2020], experts in the fields of immuno-oncology, epigenetics, tumor cell signaling, and cancer metabolism shared their latest knowledge on the roles of i] epigenetics, and in particular, chromatin modifiers, ii] cancer metabolism, iii] cancer stem cells [CSCs], iv] tumor cell signaling, and iv] the immune system. The novel therapeutic approaches presented included epigenetic drugs, cell cycle inhibitors combined with ICB, antibiotics and other off-label drugs, small-molecules active against CSCs, liposome-delivered miRNAs, tumor-specific CAR-T cells, and T-cell–based immunotherapy. Moreover, important evidence on possible mechanisms of resistance to these innovative therapies were also discussed, in particular with respect to resistance to ICB. Overall, this conference provided scientists and clinicians with a broad overview of future challenges and hopes to improve cancer treatment reasonably in the medium-short term.

AB - During the Tenth Edition of the Annual Congress on “Anticancer Innovative Therapy” [Milan, 23/24 January 2020], experts in the fields of immuno-oncology, epigenetics, tumor cell signaling, and cancer metabolism shared their latest knowledge on the roles of i] epigenetics, and in particular, chromatin modifiers, ii] cancer metabolism, iii] cancer stem cells [CSCs], iv] tumor cell signaling, and iv] the immune system. The novel therapeutic approaches presented included epigenetic drugs, cell cycle inhibitors combined with ICB, antibiotics and other off-label drugs, small-molecules active against CSCs, liposome-delivered miRNAs, tumor-specific CAR-T cells, and T-cell–based immunotherapy. Moreover, important evidence on possible mechanisms of resistance to these innovative therapies were also discussed, in particular with respect to resistance to ICB. Overall, this conference provided scientists and clinicians with a broad overview of future challenges and hopes to improve cancer treatment reasonably in the medium-short term.

KW - Innovative therapy

KW - Targeted therapy

UR - http://www.scopus.com/inward/record.url?scp=85101123775&partnerID=8YFLogxK

U2 - 10.1016/j.cytogfr.2021.02.001

DO - 10.1016/j.cytogfr.2021.02.001

M3 - Review article

C2 - 33610464

AN - SCOPUS:85101123775

SN - 1359-6101

VL - 59

SP - 1

EP - 8

JO - Cytokine and Growth Factor Reviews

JF - Cytokine and Growth Factor Reviews

ER -

Anticancer innovative therapy congress: Highlights from the 10th anniversary edition

Abstract

Keywords

Access to Document

Fingerprint

Cite this